PRAX: Praxis Precision Medicines, Inc.
About
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
Current Value
$72.591 Year Return
Current Value
$72.591 Year Return
Key Details
Market Cap
$1.36B
P/E Ratio
-7.07
1Y Stock Return
353.27%
1Y Revenue Growth
-16.93%
Dividend Yield
0.00%
Price to Book
3.4
Strategies that include PRAX
Stock's related to PRAX
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FRPT | 0.01% | $7.59B | +126.44% | 0.00% |
| VERX | 0.01% | $7.99B | +89.70% | 0.00% |
| ORLY | -0.02% | $69.31B | +22.06% | 0.00% |
| IIPR | -0.02% | $3.01B | +33.85% | 7.00% |
| OII | 0.05% | $2.78B | +32.07% | 0.00% |
| HPK | -0.06% | $1.86B | -9.44% | 0.81% |
| NOC | 0.07% | $71.54B | +4.23% | 1.60% |
| CMBT | 0.07% | $2.46B | -29.63% | 13.05% |
| REPX | -0.08% | $745.24M | +32.40% | 4.19% |
| CEIX | -0.10% | $3.72B | +24.89% | 0.39% |
| DCOM | 0.10% | $1.52B | +72.79% | 2.89% |
| RNR | 0.11% | $13.74B | +23.09% | 0.58% |
| TEL | -0.11% | $43.96B | +12.42% | 1.28% |
| RTX | 0.12% | $158.34B | +52.22% | 2.09% |
| UUU | 0.12% | $4.97M | -41.89% | 0.00% |
| ALL | 0.13% | $52.06B | +45.67% | 1.85% |
| CIVI | -0.15% | $4.91B | -21.31% | 3.94% |
| X | 0.15% | $8.76B | +13.32% | 0.51% |
| CTVA | 0.16% | $40.03B | +25.87% | 1.11% |
| CSL | 0.16% | $19.72B | +59.12% | 0.85% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CME | -15.11% | $82.76B | +9.21% | 1.98% |
| CNK | -14.61% | $4.09B | +138.59% | 0.00% |
| DADA | -13.01% | $367.07M | -63.71% | 0.00% |
| GPRK | -12.79% | $440.00M | -9.95% | 6.37% |
| CVX | -12.13% | $286.82B | +10.80% | 4.08% |
| FLG | -11.81% | $4.52B | -59.98% | 0.65% |
| SKM | -11.56% | $8.53B | -0.67% | 6.32% |
| TSN | -11.43% | $21.95B | +31.14% | 3.11% |
| GIS | -10.94% | $34.85B | -2.91% | 3.78% |
| GRFS | -10.92% | $2.18B | -11.41% | 0.00% |
| LOGC | -10.84% | $182.42M | +43.98% | 0.00% |
| TBRG | -10.65% | $244.47M | +52.66% | 0.00% |
| HAYN | -10.02% | $779.50M | +25.76% | 1.44% |
| APA | -9.90% | $8.11B | -40.14% | 4.54% |
| AMED | -9.78% | $2.95B | -3.95% | 0.00% |
| HES | -9.25% | $45.06B | +1.32% | 1.24% |
| XOM | -8.88% | $521.39B | +13.56% | 3.22% |
| UNFI | -8.64% | $1.31B | +44.06% | 0.00% |
| K | -8.40% | $27.77B | +52.50% | 2.79% |
| STG | -8.25% | $35.67M | +7.92% | 0.00% |
ETF's related to PRAX
News
SeekingAlpha
Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.
Yahoo
Praxis Precision Medicines ( NASDAQ:PRAX ) Third Quarter 2024 Results Key Financial Results Net loss: US$51.9m (loss...
Yahoo
Praxis Precision Medicines Inc (PRAX) reports robust financial health and significant progress in its clinical pipeline, despite some strategic delays.
Yahoo
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024. Praxis management will participate in a fireside chat at the Truist Securities BioPharma S
Yahoo
Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of -36.82% and 42.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) Vormatrigine (PRAX-628) on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epil
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.